# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death thro...
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery ...
Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and rai...
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of ...
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resis...